Trial · NCT04069260
A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis
NCT04069260, Phase 2, Terminated, Eloxx Pharmaceuticals, Inc.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis. Trials, record NCT04069260. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04069260
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis
- NCT number
- NCT04069260
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- Eloxx Pharmaceuticals, Inc.
- Conditions
- Genetic Disease, Nonsense Mutation, Cystinosis
- Interventions
- ELX-02
- First posted
- 2019-08-28
- Last updated
- 2020-05-27
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | AEs associated with different dose levels of ELX-02 | From the time of first dosing through the follow-up visit, an average of approximately 10 weeks | |
| Primary | Area under the plasma concentration curve from time zero to 24 hours (AUC0-24h) | Day 1 of treatment periods 1, 2, and 3 | Full PK profile 12 blood samples over 24 hours |
| Primary | Maximum observed plasma concentration (Cmax) | Day 1 of treatment periods 1, 2, and 3 | Full PK profile 12 blood samples over 24 hours |
| Primary | Observed plasma concentration at 1 hour post dose (C1h) | Days 1, 2, 5, and 7 of treatment periods 1-2; Days 1, 2, 5, 7, 10, and 14 of treatment period 3 | Sparse sampling, blood sampling only, pre-dose and 1 hour post dose |
| Primary | Amount of ELX-02 excreted in urine from 0 to 24 hours (Ae24h) | Day 1 of treatment periods 1, 2, and 3 | 6 urine collections over 24 hours |
| Primary | Renal clearance on Day 1 (Ae24h/plasma AUC0-24h) | Day 1 of treatment periods 1, 2, and 3 | 6 urine collections over 24 hours |
| Secondary | Changes from baseline in WBC cystine levels | Screening; Days 1, 2, 5, and 7 of treatment periods 1-2; Days 1, 2, 5, 7, 10, and 14 of treatment period 3, and 4-week safety follow-up |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04069260
GET https://conductscience.org/api/trials/v1/NCT04069260/registered